CVE Intelligence
High Privilege escalation

CVE-2026-83193 — Vulnerability in the Siebel Apps - Life Sciences product of Oracle Siebel CRM…

Vulnerability in the Siebel Apps - Life Sciences product of Oracle Siebel CRM (component: Life Sciences). Supported versions that are affected are 17.0-26.7. Easily exploitable vulnerability allows low privileged attacker with logon to the infrastructure where Siebel Apps - Life Sciences executes to compromise Siebel Apps - Life Sciences. Successful attacks require human interaction from a person other than the attacker. Successful attacks of this vulnerability can result in takeover of Siebel Apps - Life Sciences. CVSS 3.1 Base Score 7.3 (Confidentiality, Integrity and Availability impacts). CVSS Vector: (CVSS:3.1/AV:L/AC:L/PR:L/UI:R/S:U/C:H/I:H/A:H).

Published Sep 15, 2026 · Updated Oct 15, 2026 · Sources: NIST National Vulnerability Database · CNA: secalert_us@oracle.com

Who exploits it and how urgent it is

A 0–100 score combining confirmed exploitation, ransomware and APT use, public exploits, EPSS and severity.

No exploitation signal in the sources consulted so far.
How the score was calculated
  • Technical severity (high)+6

The score orders the patch queue; it does not replace your asset context (internet exposure, criticality, compensating controls).

Triage

Is it exploited, how likely is exploitation, what does it touch, and how severe do the sources call it.

Exploitation
Not confirmed
Not in CISA KEV — an absence of record, not proof it is unexploited.
EPSS FIRST
—
No EPSS score.
Affects
—
Affected products not yet identified by the sources.
CVSS base
7.3
High · 1 source(s)

Remediation

Fixes and mitigations documented by the sources — linked to the original advisory.

No fix documented by the sources we poll. That does not mean none exists: check the vendor advisory.

First 24 hours

Ordered from the record’s own fields — exposure first, because you cannot patch what you have not found. A rule-generated starting point.

  1. Affected products have not been identified by the sources yet: follow the vendor advisory and map candidate assets by component name.
  2. No fix documented in the sources: reduce exposure and monitor the vendor advisory.
  3. Exploitation requires user interaction: tighten email/web filtering and warn affected users.
  4. Search available logs for exploit probes matching the vulnerability class (privilege escalation), errors and authentication anomalies.

Affected scope

Vendor, product and versions as the sources word them.

Affected products not yet identified by the sources.

Attack characteristics

The CVSS vector, decoded. It describes the attack, not your exposure to it.

Attack vector
Local
Attack complexity
Low
Privileges required
Low
User interaction
Required
Scope
Unchanged
Confidentiality
High
Integrity
High
Availability
High

Every base score collected

Sources score independently and may disagree; each row says who scored it and under which version.

ScoreVersionSeverityExpl.ImpactScored by
7.3 CVSS 3.1 High 1.3 5.9 secalert_us@oracle.com via NIST National Vulnerability Database
CVSS:3.1/AV:L/AC:L/PR:L/UI:R/S:U/C:H/I:H/A:H (score shown at the top: secalert_us@oracle.com)

Weakness MITRE

Weakness class according to MITRE’s CWE catalog.

CWE-269 · Improper Privilege Management

Other CVEs with this weakness →

Detection

Read off the CVSS vector and the weakness class. Starting points, not tested rules.

  • Local/physical vector: focus on endpoint telemetry (EDR) from affected hosts.
endpoint telemetry (EDR)

Timeline

What happened to this CVE, newest first.

  • 2026
  • Record published
    Oct 15, 2026
  • CVSS changed · 7.3
    Oct 15, 2026 · NIST National Vulnerability Database
  • Source status changed · → Deferred
    Oct 15, 2026 · NIST National Vulnerability Database
  • Record created in this database
    Oct 15, 2026 · NIST National Vulnerability Database
  • CVE published
    Sep 15, 2026 · secalert_us@oracle.com

Source activity

Repeated readings are counted rather than listed.

  • 1× Official description updated · Oct 15, 2026 – Oct 15, 2026

References

1 on the record

Elsewhere on this site

Privilege escalation
same class
CWE-269
other pages naming this weakness

Not in any source we poll

Listed rather than left blank: an empty field and an unmeasured one look identical on screen, and only one is a reason to look elsewhere.

  • No FIRST EPSS score.
  • No affected product/version with evidence in the sources.
  • No fixed version, patch or mitigation documented.
  • No CISA SSVC assessment.
  • No confirmed IOCs, IP addresses, domains, file hashes, or malware artifacts supplied.
  • No organization-specific asset inventory, compensating-control status, or patch deployment evidence supplied.
  • No exploit packet captures, log samples, or incident case IDs supplied.

Answered from this record

Text assembled only from the fields above — no additional claims.

What should defenders know first?

CVE-2026-83193 is "Vulnerability in the Siebel Apps - Life Sciences product of Oracle Siebel CRM…", rated High. Affected products have not been identified by the sources yet. It is not in CISA KEV, which does not rule out exploitation. CVSS 7.3 describes technical severity. First verify whether exposed or business-critical assets run the affected versions, apply vendor fixes or mitigations, and preserve logs for review.

Comments

Moderated technical discussion. Read the community guidelines.

No comments yet.

Sign in or create an account to comment and suggest corrections.